Case report
Open access
Jul 2026
Onatasertib re-sensitizes refractory nasopharyngeal carcinoma to immunotherapy: a Case Report
A case study highlighting the significant efficacy of onatasertib, a dual mechanistic target of rapamycin (mTOR) 1/2 inhibitor, in overcoming resistance to immunotherapy in patients with R/M-NPC.
Peipei Zhang, Zhanpeng Zhang, Jun Liu et al.
· Frontiers in Pharmacology · 0 citations